UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063668
Receipt number R000072871
Scientific Title Long-term outcomes of four-fraction carbon-ion radiotherapy for intermediate-risk prostate cancer: A Phase I/II dose-escalation trial
Date of disclosure of the study information 2026/11/17
Last modified on 2026/11/17 19:23:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Long-term outcomes of four-fraction carbon-ion radiotherapy for intermediate-risk prostate cancer: A Phase I/II dose-escalation trial

Acronym

Long-term Outcomes of Four-Fraction CIRT for Intermediate-Risk Prostate Cancer

Scientific Title

Long-term outcomes of four-fraction carbon-ion radiotherapy for intermediate-risk prostate cancer: A Phase I/II dose-escalation trial

Scientific Title:Acronym

Long-term Outcomes of Four-Fraction CIRT for Intermediate-Risk Prostate Cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We performed a long-term analysis of intermediate-risk patients enrolled in the trial.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

5-year biochemical recurrence-free survival (bRFS) rate

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Patients enrolled in the previous Phase I/II trial of four-fraction carbon-ion radiotherapy for low- or intermediate-risk localized prostate cancer.

Key exclusion criteria

Patients who or whose legally authorized representatives declined the use of their clinical data for this study.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Atsushi
Middle name
Last name Okato

Organization

QST Hospital, National Institutes for Quantum Science and Technology

Division name

Department of Genitourinary Oncology

Zip code

263-8555

Address

4-9-1 Anagawa, Inage-ku, Chiba

TEL

043-206-3306

Email

okato.atsushi@qst.go.jp


Public contact

Name of contact person

1st name Atsushi
Middle name
Last name Okato

Organization

QST Hospital, National Institutes for Quantum Science and Technology

Division name

Department of Genitourinary Oncology

Zip code

263-8555

Address

4-9-1 Anagawa, Inage-ku, Chiba

TEL

043-206-3306

Homepage URL


Email

okato.atsushi@qst.go.jp


Sponsor or person

Institute

QST Hospital, National Institutes for Quantum Science and Technology

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Institutes for Quantum Science and Technology Certified Review Board

Address

4-9-1 Anagawa, Inage-ku, Chiba

Tel

043-206-3306

Email

helsinki@qst.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 09 Month 28 Day

Date of IRB

2026 Year 10 Month 15 Day

Anticipated trial start date

2026 Year 12 Month 01 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a single-center, retrospective observational study involving 60 patients enrolled in a previous Phase I/II trial of four-fraction carbon-ion radiotherapy for low- or intermediate-risk localized prostate cancer.

Existing clinical data, including electronic medical records, will be retrospectively reviewed to evaluate the long-term efficacy and safety of four-fraction carbon-ion radiotherapy. The primary endpoint is the 5-year biochemical recurrence-free survival rate. Secondary endpoints include the 5-year overall survival rate, acute and late adverse events, and quality of life.

No additional therapeutic intervention will be performed in this study.


Management information

Registered date

2026 Year 11 Month 17 Day

Last modified on

2026 Year 11 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072871